Swiss Clinical Quality Management in Rheumatic Diseases
The objective of the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) is to contribute to lasting improvement in drug therapy for inflammatory rheumatism by reducing inflammatory activity and pain in the short term and damage, and consequently disability, in the long term. Within Clinical quality management (CQM), as used in Switzerland, rheumatologists are provided with a measurement feedback system with which they can regularly follow their patients. Feedback is used to optimize therapy, which in the short term allows the activity of the inflammatory process to be adjusted or 'titrated'. In the long term, the therapy result for the individual patient is monitored by the course of disability and damage.
Overview
- Acronym
- SCQM
- Website
- SCQM
- Investigators
-
- Contacts
-
General Design
- Study design
- Registry
- Start - End Year
- 1997 -
- General Information on Follow Up (profile, frequency)
-
After baseline, participants were followed-up annually at regular intervals, between 1 and 4 visits per year. Covid19 study participants were followed up from July 2020 to August 2021. Covacc study participants were followed up from February 2021 to June 2022. Vaccination study participants were followed up from September 2021 to August 2023.
- Recruitment Target
-
- Individuals
- Number of Participants
- 20,096
- Supplementary information about number of participants
-
Biological samples were collected from more than 3,300 patients and comprises more than 3,800 biokits (more than 3,500 DNA and more than 3,500 blood serum).
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Marker Papers
Uitz E, Fransen J, Langenegger T, Stucki G. Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology (Oxford). 2000;39(5):542-9.
PUBMED 10852987Ciurea A, Scherer A, Exer P, et al. Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheumatology. 2013;65(12):3096-106.
PUBMED 23983141Stekhoven D, Scherer A, Nissen MJ, et al. Swiss Clinical Quality Management for Rheumatic Diseases. Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clinical Rheumatolology. 2017;36(9):2035-2043.
PUBMED 28432523Supplementary Information
Supplemental data is available with antibody test results for covid-19 infection, antibody titres measurements pre- and up to six months post covid-19 vaccination and patient reported questionnaires around covid. Also, in a sub-group of patients, more fine grained clinical and patient reported data is available from the pregnancy and reproduction cohort.
Timeline
Populations
SCQM - RA
The population is composed of mainly adult patients with rheumatoid arthritis (RA) diagnosed by the treating rheumatologist.
Selection Criteria
- Countries
-
- Switzerland
- Health Status
-
- Clinical diagnosis or suspicion of rheumatoid arthritis
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are included in the registry by the treating rheumatologist. The inclusion of the rheumatologist and the patients in the study is voluntary.
Sample Size
- Number of Participants
- 10,721
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SCQM - RA - Baseline |
|
|
1997 | Ongoing |
| 1 | SCQM - RA - Follow-up |
|
|
1998 | Ongoing |
| 26 | SCQM - RA - Pregnancy registry preconception |
|
2017 | Ongoing | |
| 27 | SCQM - RA - Pregnancy registry conception |
|
2017 | Ongoing | |
| 28 | SCQM - RA - Pregnancy registry first trimester |
|
2017 | Ongoing | |
| 29 | SCQM - RA - Pregnancy registry second trimester |
|
2017 | Ongoing | |
| 30 | SCQM - RA - Pregnancy registry third trimester |
|
2017 | Ongoing | |
| 31 | SCQM - RA - Pregnancy registry 1 month postpartum |
|
2017 | Ongoing | |
| 32 | SCQM - RA - Pregnancy registry 2 months postpartum |
|
2017 | Ongoing | |
| 33 | SCQM - RA - Pregnancy registry 6 months postpartum |
|
2017 | Ongoing | |
| 34 | SCQM - RA - Pregnancy registry 1 year postpartum |
|
2017 | Ongoing | |
| 35 | SCQM - RA - Pregnancy registry 2 years postpartum |
|
2017 | Ongoing | |
| 36 | SCQM - RA - Pregnancy registry 4 years postpartum |
|
2017 | Ongoing | |
| 37 | SCQM - RA - Covid19 |
|
|
2020 (July) | 2021 (August) |
| 38 | SCQM - RA - Covacc |
|
2021 (February) | 2022 (June) | |
| 39 | SCQM - RA - Vaccination |
|
|
2021 (September) | 2023 (August) |
SCQM - axSpA
The population is composed of all patients with ankylosing spondylitis (AS) or other forms of spondyloarthritis (SpA) with predominantly axial disease according to the opinion of the treating rheumatologist.
Selection Criteria
- Countries
-
- Switzerland
- Health Status
-
- Clinical diagnosis or suspicion of ankylosing spondylitis or other forms of spondyloarthritis with predominantly axial
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Patients were recruited by 177 rheumatologists in private practice (52% of the patients) as well as from the rheumatology departments at 42 hospitals (including 6 academic centers) from all geographic regions in Switzerland. The inclusion of the rheumatologist and the patients in the study is voluntary.
Sample Size
- Number of Participants
- 5,412
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SCQM - axSpA - Baseline |
|
|
2005 | Ongoing |
| 1 | SCQM - axSpA - Follow-up |
|
|
2006 | Ongoing |
| 18 | SCQM - axSpA - Pregnancy registry preconception |
|
2017 | Ongoing | |
| 19 | SCQM - axSpA - Pregnancy registry conception |
|
2017 | Ongoing | |
| 20 | SCQM - axSpA - Pregnancy registry first trimester |
|
2017 | Ongoing | |
| 21 | SCQM - axSpA - Pregnancy registry second trimester |
|
2017 | Ongoing | |
| 22 | SCQM - axSpA - Pregnancy registry third trimester |
|
2017 | Ongoing | |
| 23 | SCQM - axSpA - Pregnancy registry 1 month postpartum |
|
2017 | Ongoing | |
| 24 | SCQM - axSpA - Pregnancy registry 2 months postpartum |
|
2017 | Ongoing | |
| 25 | SCQM - axSpA - Pregnancy registry 6 months postpartum |
|
2017 | Ongoing | |
| 26 | SCQM - axSpA - Pregnancy registry 1 year postpartum |
|
2017 | Ongoing | |
| 27 | SCQM - axSpA - Pregnancy registry 2 years postpartum |
|
2017 | Ongoing | |
| 28 | SCQM - axSpA - Pregnancy registry 4 years postpartum |
|
2017 | Ongoing | |
| 37 | SCQM - axSpA - Covid19 |
|
|
2020 (July) | 2021 (August) |
| 38 | SCQM - axSpA - Covacc |
|
2021 (February) | 2022 (June) | |
| 39 | SCQM - axSpA - Vaccination |
|
|
2021 (September) | 2023 (August) |
| 40 | SCQM - axSpA - Covid19 8 weeks post vaccination |
|
2020 | Ongoing | |
| 41 | SCQM - axSpA - Covid19 12 weeks post vaccination |
|
|
2020 | Ongoing |
| 42 | SCQM - axSpA - Covid19 16 weeks post vaccination |
|
2020 | Ongoing | |
| 43 | SCQM - axSpA - Covid19 20 weeks post vaccination |
|
2020 | Ongoing | |
| 44 | SCQM - axSpA - Covid19 24 weeks post vaccination |
|
|
2020 | Ongoing |
| 45 | SCQM - axSpA - Covid19 36 weeks post vaccination |
|
|
2020 | Ongoing |
| 46 | SCQM - axSpA - Covid19 48 weeks post vaccination |
|
|
2020 | Ongoing |
SCQM - PsA
The population is composed of all patients with psoriatic arthritis (PsA) diagnosed by the treating rheumatologist.
Selection Criteria
- Countries
-
- Switzerland
- Health Status
-
- Clinical diagnosis or suspicion of psoriatic arthritis
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are included in the registry by the treating rheumatologist. More than 65% of the rheumatologists, who contributed data on PsA patients, were from private practices. The inclusion of the rheumatologist and the patients in the study is voluntary.
Sample Size
- Number of Participants
- 2,892
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SCQM - PsA - Baseline |
|
|
2006 | Ongoing |
| 1 | SCQM - PsA - Follow-up |
|
|
2007 | Ongoing |
| 17 | SCQM - PsA - Pregnancy registry preconception |
|
2017 | Ongoing | |
| 18 | SCQM - PsA - Pregnancy registry conception |
|
2017 | Ongoing | |
| 19 | SCQM - PsA - Pregnancy registry first trimester |
|
2017 | Ongoing | |
| 20 | SCQM - PsA - Pregnancy registry second trimester |
|
2017 | Ongoing | |
| 21 | SCQM - PsA - Pregnancy registry third trimester |
|
2017 | Ongoing | |
| 22 | SCQM - PsA - Pregnancy registry 1 month postpartum |
|
2017 | Ongoing | |
| 23 | SCQM - PsA - Pregnancy registry 2 months postpartum |
|
2017 | Ongoing | |
| 24 | SCQM - PsA - Pregnancy registry 6 months postpartum |
|
2017 | Ongoing | |
| 25 | SCQM - PsA - Pregnancy registry 1 year postpartum |
|
2017 | Ongoing | |
| 26 | SCQM - PsA - Pregnancy registry 2 years postpartum |
|
2017 | Ongoing | |
| 27 | SCQM - PsA - Pregnancy registry 4 years postpartum |
|
2017 | Ongoing | |
| 37 | SCQM - PsA - Covid19 |
|
|
2020 (July) | 2021 (August) |
| 38 | SCQM - PsA - Covacc |
|
2021 (February) | 2022 (June) | |
| 39 | SCQM - PsA - Vaccination |
|
|
2021 (September) | 2023 (August) |
SCQM - UA
The population is composed of all patients with undifferentiated inflammatory arthritis (UA) diagnosed by the treating rheumatologist.
Selection Criteria
- Countries
-
- Switzerland
- Health Status
-
- Clinical diagnosis or suspicion of undifferentiated inflammatory arthritis
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are included in the registry by the treating rheumatologist. The inclusion of the rheumatologist and the patients in the study is voluntary.
Sample Size
- Number of Participants
- 899
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SCQM - UA - Baseline |
|
2009 | Ongoing | |
| 1 | SCQM - UA - Follow-up |
|
|
2010 | Ongoing |
| 14 | SCQM - UA - Pregnancy registry preconception |
|
2017 | Ongoing | |
| 15 | SCQM - UA - Pregnancy registry conception |
|
2017 | Ongoing | |
| 16 | SCQM - UA - Pregnancy registry first trimester |
|
2017 | Ongoing | |
| 17 | SCQM - UA - Pregnancy registry second trimester |
|
2017 | Ongoing | |
| 18 | SCQM - UA - Pregnancy registry third trimester |
|
2017 | Ongoing | |
| 19 | SCQM - UA - Pregnancy registry 1 month postpartum |
|
2017 | Ongoing | |
| 20 | SCQM - UA - Pregnancy registry 2 months postpartum |
|
2017 | Ongoing | |
| 21 | SCQM - UA - Pregnancy registry 6 months postpartum |
|
2017 | Ongoing | |
| 22 | SCQM - UA - Pregnancy registry 1 year postpartum |
|
2017 | Ongoing | |
| 23 | SCQM - UA - Pregnancy registry 2 years postpartum |
|
2017 | Ongoing | |
| 24 | SCQM - UA - Pregnancy registry 4 years postpartum |
|
2017 | Ongoing | |
| 37 | SCQM - UA - Covid19 |
|
|
2020 (July) | 2021 (August) |
| 38 | SCQM - UA - Covacc |
|
2021 (February) | 2022 (June) | |
| 39 | SCQM - UA - Vaccination |
|
|
2021 (September) | 2023 (August) |
SCQM - GCA
The population is composed of all patients with giant cell arteritis (GCA) diagnosed by the treating rheumatologist.
Selection Criteria
- Countries
-
- Switzerland
- Health Status
-
- Clinical diagnosis or suspicion of giant cell arteritis
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are included in the registry by the treating rheumatologist. The inclusion of the rheumatologist and the patients in the study is voluntary.
Sample Size
- Number of Participants
- 124
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SCQM - GCA - Baseline |
|
2020 | Ongoing | |
| 1 | SCQM - GCA - Follow-up |
|
|
2021 | Ongoing |
| 37 | SCQM - GCA - Covid19 |
|
|
2020 (July) | 2021 (August) |
SCQM - PMR
The population is composed of all patients with polymyalgia rheumatica (PMR) diagnosed by the treating rheumatologist.
Selection Criteria
- Countries
-
- Switzerland
- Health Status
-
- Clinical diagnosis or suspicion of polymyalgia rheumatica
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are included in the registry by the treating rheumatologist. The inclusion of the rheumatologist and the patients in the study is voluntary.
Sample Size
- Number of Participants
- 48
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SCQM - PMR - Baseline |
|
2020 | Ongoing | |
| 1 | SCQM - PMR - Follow-up |
|
|
2021 | Ongoing |
| 37 | SCQM - PMR - Covid19 |
|
|
2020 (July) | 2021 (August) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2024-08-12T15:06:05.480